Related Experiment Video

Updated: Jul 19, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Genetic variation in susceptibility to endocrine disruption by estrogen in mice

J L Spearow1, P Doemeny, R Sera

  • 1Section of Neurobiology, Physiology and Behavior, University of California at Davis, Davis, CA 95616, USA. jlspearow@ucdavis.edu

Science (New York, N.Y.)
|August 24, 1999
PubMed

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice07:12

A Syngeneic Murine Model of Endometriosis using Naturally Cycling Mice

Published on: November 24, 2020

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...